FACSIMILE TRANSMIS Ticket Number:				Study #: E FAX NO: (301) 230-0159 E FAX NO: (301) 897-7404
Initial Report Date:		Follow-up Report Date:		
Principal Investigator:		Reporter:		
Reporter Telephone #:		Reporter FAX #:		
Investigator Number Complete all of the investigator and subject number boxes provided. Use le when necessary, to complete all expected boxes. Example: Investigator #407 would be filled in as: 0 0 4 0		ding zeros,	Record the first letter	Subject Initials of the subject's first, middle and last be. If the subject has no middle name, slee: A - C
Subject's Sex:	Subject's Weight	ght: Subject's Date of Birth		of Birth:
(ab a als all that apply)	Study Drug Stop Date:	Islander		frican American of Available Study Drug Continuing
Dose:	Route: ORAL	Frequenc	y: QD	Kit #:
First Day of Last Menstrual Peri Method of Contraception (check	DD MMM YY	Estima	ated Date of Delivery	DD MMM YY
Oral Contraceptive Pills			Progestin Injection ther, specify:	or Implants Spermacide
Reproductive History: Gravi	da Para			
Tests performed during pregnand CVS Results: Norma	Amniocentesis Res	sults: No	ormal Ultras	ound Results: Normal Abnormal
Date of Termination:	ated, specify pregnancy outcomature OR Normal Abnormal		ovide infant outcome	
1				
NOTE: For an initial reporting	for both the Drognonov Do	CDF		

NOTE: The patient should have appropriate follow-up as deemed necessary by their physician. If the the baby is born with a birth defect or anomaly, then a second AdEERS/CTEP-AERS report is required.

1.0